Navigation Links
Repligen Reports Fourth Quarter and Fiscal Year 2009 Financial Results
Date:6/11/2009

83 30,957,957 30,834,491 Diluted 30,961,807 31,064,483 31,290,233 31,320,997 Balance Sheet Data: March 31, 2009 March 31, 2008 Cash, cash equivalents and marketable securities* $63,960,564 $60,589,054 Working capital 50,234,803 49,831,376 Total assets 73,754,742 68,839,707 Long-term obligations 82,398 143,043 Accumulated deficit (113,857,261) (120,576,820) Stockholders' equity 69,123,431 64,106,854 *does not include restricted cash

This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, statements regarding current or future financial performance and position, management's strategy, plans and objectives for future operations, plans and objectives for product development, plans and objectives for present and future clinical trials and results of such trials, plans and objectives for regulatory approval, litigation, intellectual property, product development, manufacturing plans and performance such as the anticipated growth in the monoclonal antibody market and our other target markets and projected growth in product sales, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated,
'/>"/>

SOURCE Repligen Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Repligen Announces Conference Call of Fourth Quarter and Fiscal Year 2009 Results
2. Repligen to Present at the Cowen and Company 29th Annual Healthcare Conference Monday, March 16th, 2:25 p.m. EDT
3. Repligen Reports Third Quarter Fiscal Year 2009 Financial Results
4. Repligen to Present at the BIO CEO & Investor Conference Monday, February 9th, 11:30 a.m. EST
5. Repligen Announces Conference Call of Third Quarter Fiscal Year 2009 Results
6. Repligen to Present at the Rodman & Renshaw 10th Annual Healthcare Conference Monday, November 10th, 4:55 p.m. EST
7. Repligen to Present at the 2008 UBS Global Life Sciences Conference Wednesday, September 24th, 1:00 p.m. EDT
8. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
9. Repligen Receives Research Grants to Support Friedreichs Ataxia Development Program
10. Repligen Announces Conference Call of First Quarter Fiscal Year 2009 Results
11. Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... 30, 2015  Roka Bioscience, Inc. (NASDAQ: ROKA ... testing solutions for the detection of foodborne pathogens, announced ... quarter of 2015 on May 7, 2015 after the ... will also host a conference call at 4:30 p.m. ... first quarter financial results. During the conference call, material ...
(Date:4/30/2015)... April 30, 2015 Cytokinetics, Incorporated (Nasdaq: CYTK) ... of 2015 were $4.4 million, compared to $8.0 million during ... the first quarter was $8.9 million, or $0.23 per basic ... for the same period in 2014, of $8.7 million, or ... 31, 2015, cash, cash equivalents and investments totaled $117.5 million. ...
(Date:4/30/2015)... Nitto Avecia, a leading biotechnology manufacturer and ... production capability to serve biotechnology pharmaceutical clients. A ... continues to drive Nitto Avecia to enhance synthesis ... , In Fall 2014, Nitto Avecia first ... its Milford, MA facility, which is recognized as ...
(Date:4/30/2015)... 30, 2015 The following is an open letter ... China Cord Blood Corp (NYSE: CO ) from Jayhawk ... the independent directors of China Cord Blood Corp (" China ... $6.40 per share from Golden Meditech Holdings Co Ltd ("Golden ... would greatly benefit Golden Med and Mr. Kam, the Chairman ...
Breaking Biology Technology:Roka Bioscience to Report First Quarter 2015 Financial Results On May 7, 2015 2Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 2Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 3Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 4Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 5Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 6Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 7Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 8Biotechnology Manufacturer Nitto Avecia Expands Capacity to Meet Client Demand 2April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 2April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 3April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 4April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 5
... International,Corporation (Nasdaq: PRXL ) announced today that ... be presenting at the Thomas,Weisel Partners Healthcare Conference ... September 7th at 8:35 a.m. ET. A live ... "Investor Relations Webcasts",section of PAREXEL,s web site at ...
... 5 Hyperion,Therapeutics, a biopharmaceutical company focused on ... for the,treatment of Urea Cycle Disorders (UCD) and ... B financing. Leading the round was,Sofinnova Ventures, with ... of Menlo Park, CA. WRF Capital of Seattle, ...
... Cryopreservation Expert, BOTHELL, Wash., Sept. 5 ... developer and marketer of,proprietary hypothermic storage and cryopreservation ... the expansion of its Scientific,Advisory Board (SAB) with ... quality and regulatory assurance and in cryopreservation of ...
Cached Biology Technology:PAREXEL International to Present at Thomas Weisel Partners Healthcare Conference 2Hyperion Therapeutics Secures $40 Million In Series B Round 2BioLife Solutions Expands Scientific Advisory Board 2BioLife Solutions Expands Scientific Advisory Board 3BioLife Solutions Expands Scientific Advisory Board 4
(Date:3/24/2015)... 2015   NexID Biometrics LLC, whose spoof-mitigation ... today announced the beginning of shipments of version 2.0 ... The company, based in Potsdam, N.Y. ... Expo, which began here today at the Walter E. ... of its SDK boosts the accuracy rate range to ...
(Date:3/23/2015)... March 23, 2015 SoundView Technology Group issues a ... NXTD ) Wocket smart wallet. SoundView was one of the ... their experience with the Wocket in multiple scenarios and outlets. ... Foods and other retailers, making both debit and credit card ... also says, "If the company meets their plans in 2015, ...
(Date:3/23/2015)... -- In the 2014 fiscal year, irs.gov recorded over $100 ... accounts for a fraction of the estimated losses for ... $11 billion globally. The polygraph has traditionally been used ... Investor Mark Saint Juste along with former ... partnered to administer the test in a new way: ...
Breaking Biology News(10 mins):NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3
... unused agricultural land could produce enough biomass to meet ... the environment, according to research led by Professor Gail ... funded by the UK Energy Research Centre (UKERC), is ... at the potential of planting short rotation coppice (poplar ...
... will not only teach us more about the way neurons ... diagnostics and therapies for neurological diseases such as Parkinson,s," says ... take a major toll on society. More than 8% of ... cent suffers from a mental disturbance and the number of ...
... Avila Therapeutics, Inc., a biotechnology company developing novel ... a scientific review article in Nature Reviews Drug ... www.nature.com/reviews/drugdisc , Vol. 10, April 2011, Singh, J.). ... and how structural bioinformatics coupled with structure-based drug design ...
Cached Biology News:Short rotation energy crops could help meet UK's renewable energy targets 2Skywalker ensures optimal communication between neurons 2New opportunities for covalent drugs published by Avila scientists 2
... excluding l-[U-14C]methionine, 1.85 MBq, 50 uCi. ... > 1.85 GBq/mg atom carbon, ... Mixture of Ala, Arg, Asp, Glu, ... Pro, Ser, Thr, Tyr and Val.1.85 ...
Topoisomerase I, isolated from wheat germ, is an enzyme capable of removing negative supercoils from covalently closed circular DNA (1)....
Request Info...
... Checker Kits provide two highly efficient methods ... time-consuming plasmid preparation. By using the large-scale ... need to do is to transfer partial ... the transformation plates into the solutions provided ...
Biology Products: